Literature DB >> 25190737

Survey of the bp/tee genes from clinical group A streptococcus isolates in New Zealand - implications for vaccine development.

John D Steemson1,2, Nicole J Moreland3,1, Deborah Williamson4,3,2, Julie Morgan4, Philip E Carter4, Thomas Proft3,2.   

Abstract

Group A streptococcus (GAS) is responsible for a wide range of diseases ranging from superficial infections, such as pharyngitis and impetigo, to life-threatening diseases, such as toxic shock syndrome and acute rheumatic fever (ARF). GAS pili are hair-like extensions protruding from the cell surface and consist of highly immunogenic structural proteins: the backbone pilin (BP) and one or two accessory pilins (AP1 and AP2). The protease-resistant BP builds the pilus shaft and has been recognized as the T-antigen, which forms the basis of a major serological typing scheme that is often used as a supplement to M typing. A previous sequence analysis of the bp gene (tee gene) in 39 GAS isolates revealed 15 different bp/tee types. In this study, we sequenced the bp/tee gene from 100 GAS isolates obtained from patients with pharyngitis, ARF or invasive disease in New Zealand. We found 20 new bp/tee alleles and four new bp/tee types/subtypes. No association between bp/tee type and clinical outcome was observed. We confirmed earlier reports that the emm type and tee type are associated strongly, but we also found exceptions, where multiple tee types could be found in certain M/emm type strains, such as M/emm89. We also reported, for the first time, the existence of a chimeric bp/tee allele, which was assigned into a new subclade (bp/tee3.1). A strong sequence conservation of the bp/tee gene was observed within the individual bp/tee types/subtypes (>97 % sequence identity), as well as between historical and contemporary New Zealand and international GAS strains. This temporal and geographical sequence stability provided further evidence for the potential use of the BP/T-antigen as a vaccine target.
© 2014 The Authors.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25190737     DOI: 10.1099/jmm.0.080804-0

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  8 in total

1.  Group A Streptococcus T Antigens Have a Highly Conserved Structure Concealed under a Heterogeneous Surface That Has Implications for Vaccine Design.

Authors:  Paul G Young; Jeremy M Raynes; Jacelyn M Loh; Thomas Proft; Edward N Baker; Nicole J Moreland
Journal:  Infect Immun       Date:  2019-05-21       Impact factor: 3.441

Review 2.  Tissue tropisms in group A Streptococcus: what virulence factors distinguish pharyngitis from impetigo strains?

Authors:  Debra E Bessen
Journal:  Curr Opin Infect Dis       Date:  2016-06       Impact factor: 4.915

3.  Identification and Characterization of Serotype-Specific Variation in Group A Streptococcus Pilus Expression.

Authors:  Gregory Calfee; Jessica L Danger; Ira Jain; Eric W Miller; Poulomee Sarkar; Brian Tjaden; Bernd Kreikemeyer; Paul Sumby
Journal:  Infect Immun       Date:  2018-01-22       Impact factor: 3.441

4.  Serological Evidence of Immune Priming by Group A Streptococci in Patients with Acute Rheumatic Fever.

Authors:  Jeremy M Raynes; Hannah R C Frost; Deborah A Williamson; Paul G Young; Edward N Baker; John D Steemson; Jacelyn M Loh; Thomas Proft; P R Dunbar; Polly E Atatoa Carr; Anita Bell; Nicole J Moreland
Journal:  Front Microbiol       Date:  2016-07-22       Impact factor: 5.640

5.  Mucosal vaccination with pili from Group A Streptococcus expressed on Lactococcus lactis generates protective immune responses.

Authors:  Jacelyn M S Loh; Natalie Lorenz; Catherine J-Y Tsai; Adrina Hema J Khemlani; Thomas Proft
Journal:  Sci Rep       Date:  2017-08-03       Impact factor: 4.379

Review 6.  Genetics, Structure, and Function of Group A Streptococcal Pili.

Authors:  Masanobu Nakata; Bernd Kreikemeyer
Journal:  Front Microbiol       Date:  2021-02-09       Impact factor: 5.640

7.  Pilus proteins from Streptococcus pyogenes stimulate innate immune responses through Toll-like receptor 2.

Authors:  Risa Takahashi; Fiona J Radcliff; Thomas Proft; Catherine J-Y Tsai
Journal:  Immunol Cell Biol       Date:  2022-02-24       Impact factor: 5.853

8.  A multivalent T-antigen-based vaccine for Group A Streptococcus.

Authors:  Jacelyn M S Loh; Tania Rivera-Hernandez; Reuben McGregor; Adrina Hema J Khemlani; Mei Lin Tay; Amanda J Cork; Jeremy M Raynes; Nicole J Moreland; Mark J Walker; Thomas Proft
Journal:  Sci Rep       Date:  2021-02-23       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.